Errant Gene Therapeutics Becomes San Rocco Therapeutics
Errant Gene Therapeutics Becomes San Rocco Therapeutics Errant Gene Therapeutics was founded in 1993, after founder Pat Girondi's son was diagnosed with Thalassemia, a cousin disease to Sickle Cell Anemia. In 2007, with the help of researchers from Memorial Sloan Kettering, Cornell and National Institute of Health, EGT became the first entity to pass the FDA Recombinant DNA Committee for gene therapy in Sickle Cell Disease and Beta Thalassemia. EGT was the first company to get Orphan Drug Designation for Thalassemia in the US and Europe and first to produce a commercial batch (8-10 patients) ...
Source: finanznachrichten.de